Pharmaceuticals News

Idorsia will host an investor webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO (aprocitentan).

November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the...

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem...

Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...

NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent...

New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden reductions in FAP, with activity throughout the GI tract and in...

Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the...

Châtillon, France, le 2 novembre (22 :30 CEST) 2026 DBV Technologies participera aux prochaines Conférences Investisseurs en novembre DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq...